The path to personalised medicine in COPD. (Q38208185)

31 August 2017

The path to personalised medicine in COPD. (English)

1 reference

31 August 2017

Alvar Agusti

1

1 reference

PubMed ID

24781218

31 August 2017

language of work or name

English

0 references

publication date

29 April 2014

1 reference

31 August 2017

1 reference

31 August 2017

69

1 reference

31 August 2017

857-864

1 reference

31 August 2017

9

1 reference

Addressing the complexity of chronic obstructive pulmonary disease: from phenotypes and biomarkers to scale-free networks, systems biology, and P4 medicine

31 August 2017

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Characterisation of COPD heterogeneity in the ECLIPSE cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Phenotypes and disease characterization in chronic obstructive pulmonary disease. Toward the extinction of phenotypes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

The many "small COPDs": COPD should be an orphan disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Global initiative for asthma (GINA) and its objectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Global burden of COPD: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Systemic effects in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

FAQs about the GOLD 2011 assessment proposal of COPD: a comparative analysis of four different cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Proportional classifications of COPD phenotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Chronic Obstructive Pulmonary Disease, inflammation and co-morbidity--a common inflammatory phenotype?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

The human phenome project

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Chronic obstructive pulmonary disease phenotypes: the future of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

The COPD control panel: towards personalised medicine in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

The nature of small-airway obstruction in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Multidimensional assessment and tailored interventions for COPD: respiratory utopia or common sense?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Predisposing factors to bacterial colonization in chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Persistent colonization by Haemophilus influenzae in chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Bacterial colonization increases daily symptoms in patients with chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

The lung microbiome. A new frontier in pulmonary medicine: introduction and perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

The lung microbiome. A new frontier in pulmonary medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Chronic obstructive pulmonary disease and infection. Disruption of the microbiome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Microbiome diversity in the bronchial tracts of patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Outgrowth of the bacterial airway microbiome after rhinovirus exacerbation of chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Significance of the microbiome in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Significance of the microbiome in obstructive lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

The lung microbiome and viral-induced exacerbations of chronic obstructive pulmonary disease: new observations, novel approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

The lung microbiome in moderate and severe chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

The lung tissue microbiome in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

The natural history of chronic airflow obstruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Changes in forced expiratory volume in 1 second over time in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Optical imaging of molecular signatures in pulmonary inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Visualization of pulmonary inflammation using noninvasive fluorescence molecular imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Molecular imaging: the vision and opportunity for radiology in the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Diagnosis of chronic obstructive pulmonary disease in lung cancer screening Computed Tomography scans: independent contribution of emphysema, air trapping and bronchial wall thickening

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Results of initial low-dose computed tomographic screening for lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Exploring the impact of screening with low-dose CT on lung cancer mortality in mild to moderate COPD patients: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Factors associated with bronchiectasis in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Cardiovascular comorbidity in COPD: systematic literature review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Current controversies and future perspectives in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Network medicine: a network-based approach to human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Systems medicine and integrated care to combat chronic noncommunicable diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

GOLD COPD categories are not fit for purpose in primary care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Tiotropium versus salmeterol for the prevention of exacerbations of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Effect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

I have taken my umbrella, so of course it does not rain

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Moving from the Oslerian paradigm to the post-genomic era: are asthma and COPD outdated terms?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

What Is Chronic Obstructive Pulmonary Disease Anyway?. Continua, Categories, Cut Points, and Moving beyond Spirometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Chronic Obstructive Pulmonary Disease Biomarker(s) for Disease Activity Needed—Urgently

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Systemic effects of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Chronic Obstructive Pulmonary Disease: Beyond the Forced Expiratory Manoeuvre

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

From COPD to chronic systemic inflammatory syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

Avoiding confusion in COPD: from risk factors to phenotypes to measures of disease characterisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205507

10.1136/THORAXJNL-2014-205507

21 January 2018

Identifiers

DOI

1 reference

31 August 2017

1 reference

PubMed ID

24781218